Sanofi Caps Out-Of-Pocket Insulin Cost at $35 for Uninsured U.S. Patients | Top News

by cloudnewsmag

(Reuters) – French drugmaker Sanofi said on Wednesday uninsured diabetes patients in the United States will pay no more than $35 for 30-day supply of insulin, in the wake of heightened public scrutiny over soaring prices of the life-saving drug.

U.S. lawmakers have pulled up healthcare companies over rising costs of insulin and the U.S. House of Representatives in March passed a bill capping monthly out-of-pocket insulin costs for those with health insurance at $35.

Sanofi with Eli Lilly and Co and Novo Nordisk make up 90% of the U.S. market for insulin. In 2020, Lilly announced a new co-pay scheme that covers most of its insulin products, capping the out-of-pocket cost for insulin to $35 per month.

Around 37.3 million Americans, or 11.3% of the population, have diabetes, according to the American Diabetes Association.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

Related Posts

%d bloggers like this: